Amarin and KOWA had differing perspectives entering their deal.....Amarin needed more reps and could not afford them. KOWA was promoting PITIVASTIN and saw this deal as a way to increase the sales of their statin, by reps who were visiting Docs,who might be interested in both products.....and,at the same time KOWA might earn some cash from royalties and fees(like the break up fee).....there were rumors that KOWA was not breaking a sweat to market Vascepa....some rumors that they were not always mentioning Vascepa to their Docs ...... Each side seems to have gotten what they wanted from the parternersip...... and now its probably time for each to go their respective ways.
News 
Market Data 
Discover 
